Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Chong Kun Dang Pharmaceutical Corp (CKD Pharm) -Company Report'
Title Publication Date Price Relevance
Chong Kun Dang Pharmaceutical Corp. (CKD Pharm)-Therapeutic Competitors Report Mar 2011 £220 100%
CHONG KUN DANG PHARMACEUTICAL CORP. – Product Pipeline Review
H2 2011
 Nov 2011 £315 68%
Chronic Stable Angina Global Clinical Trials Review
Q2, 2011
 May 2011 £630 49%
Angina (Angina Pectoris) Global Clinical Trials Review
H2, 2011
 Dec 2011 £630 48%
Small-Cell Lung Cancer Global Clinical Trials Review
H1, 2012
 Jan 2012 £630 47%
Male Sexual Dysfunction - Pipeline Review
H2 2011
 Aug 2011 £315 45%
Erectile Dysfunction - Pipeline Review
H2 2011
 Sep 2011 £315 45%
Colorectal Cancer - Pipeline Review
H2 2011
 Sep 2011 £315 44%
Type 2 Diabetes - Pipeline Review
H2 2011
 Sep 2011 £315 42%
Non-Small Cell Lung Cancer - Pipeline Review
H2 2011
 Sep 2011 £315 42%
Diabetes - Pipeline Review
H2 2011
 Oct 2011 £315 41%
Hypertension - Pipeline Review
Q1 2011
 Feb 2011 £315 39%
Hypertension - Pipeline Review
H2 2011
 Sep 2011 £315 37%
Botanical and Plant-Derived Drugs: Global Markets Jan 2009 £3,065 35%
Sarcomas - Pipeline Review
Q3 2011
 Jul 2011 £315 33%